Auris O Huen, MD, PharmD

Peer-Reviewed Articles

1. Lauck K, Ahmad AS, Nguyen QD, Yang Z, Kundu S, Huen AO. Management strategies and survival in cutaneous B-cell lymphoma: A population based study. JAAD Int 13:28-29, 2023. e-Pub 2023. PMID: 37592974.
2. Nguyen CN, Iyer SP, Duvic M, Barde PJ, Nair A, Routhu KV, Huen AO. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome. Invest New Drugs 41(2):350-355, 2023. e-Pub 2023. PMID: 37004644.
3. Seervai RNH, Friske SK, Chu EY, Phillips R, Nelson KC, Huen A, Cho WC, Aung PP, Torres-Cabala CA, Prieto VG, Curry JL. The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy. J Cutan Pathol 50(1):72-95, 2023. e-Pub 2022. PMID: 36069496.
4. Wu SY, Fang PQ, Wang EB, Ahmed S, Duvic M, Jain P, Castillo LEM, Nair R, Steiner RE, Strati P, Huen AO, Iyer SP, Pinnix CC, Dabaja BS, Gunther JR. Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Adv Radiat Oncol 8(6):101279, 2023. e-Pub 2023. PMID: 37448588.
5. Bur D, Patel AB, Nelson K, Huen A, Pacha O, Phillips R, Heberton M. A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. J Am Acad Dermatol 87(6):1394-1395, 2022. e-Pub 2022. PMID: 35940366.
6. Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol 158(9):1031-1039, 2022. PMID: 35857290.
7. Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2021. PMID: 34724197.
8. Bartley BR, Huen A, Rady PL, Tyring SK, Nagarajan P, Aung PP, Curry JL, Ivan D, Torres-Cabala CA, Prieto VG, Cho WC. Eosinophilic homogeneous intracytoplasmic inclusion bodies: Unique viral cytopathic changes associated with epidermodysplasia verruciformis and human papillomavirus type 49. J Cutan Pathol. e-Pub 2022. PMID: 35262953.
9. Lo JJ, Heberton MM, Pacha O, Huen AO, Patel AB. Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single institution study of 17 consecutively treated patients. Support Care Cancer, 2022. PMID: 34519869.
10. Huen AO, Kwong BY, Lacouture ME, Noor SJ, Rook AH, Seminario-Vidal L, Vermeer MH, Kim YH. Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: characterization and management. Dermatol Ther (Heidelb):29-40, 2022. PMID: 34816383.
11. Nguyen CN, Iyer SP, Miranda RN, Torres-Cabala CA, Curry JL, Fang P, Thomas VD, Huen AO. Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. JAAD Case Rep, 2021. PMID: 34692965.
12. Zinzani PL, Ortiz-Romero P, Lima M, Huen AO. Health-related quality if life effect of mogamulizumab by patient blood involvement patient blood involvement. Eur J Cancer:1:S65-S66, 2021. PMID: 34649667.
13. Collins K, Gu J, Aung PP, Nagarajan P, Curry JL, Huen A, Ivan D, Prieto VG, Tetzlaff MT, Duvic M, Miranda RN, Vega F, Torres-Cabala CA. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. Virchows Arch 479(2):377-383, 2021. e-Pub 2021. PMID: 33604757.
14. Torres-Cabala CA, Huen A, Iyer SP, Miranda RN. Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations: Challenges for Diagnosis and Classification. Surg Pathol Clin 14(2):177-194, 2021. e-Pub 2021. PMID: 34023099.
15. Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W, Jorgensen JL, Medeiros LJ, Vega F, Craig FE, Wang SA. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom 100(2):183-191, 2021. e-Pub 2020. PMID: 32667737.
16. Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk 21(2):97-105, 2021. e-Pub 2020. PMID: 33158772.
17. Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824175.
18. Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer 133:120-130, 2020. e-Pub 2020. PMID: 32502876.
19. Jenkinson HA, Aung PP, Huen A. Mycosis fungoides manifesting as a morbilliform eruption mimicking a viral exanthem. Cutis 105(6):E27-E29, 2020. PMID: 32717002.
20. Tran J, Huen A, Duvic M. Renal Cell Carcinoma Associated with Mycosis Fungoides: A Paraneoplastic Syndrome. Case Rep Nephrol 2020:8897183, 2020. e-Pub 2020. PMID: 33178469.
21. Messer A, Brown AE, Pacha O, Boddu P, Geppner A, Kadia TM, Huen AO. Successful treatment of cutaneous adult T-cell leukemia/lymphoma with imiquimod. JAAD Case Rep 5(11):979-981, 2019. e-Pub 2019. PMID: 31709290.
22. Emge DA, Bassett RL, Duvic M, Huen AO. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. Arch Dermatol Res. e-Pub 2019. PMID: 31776647.
23. Ibarra BS, Huen A, Nagarajan P, Torres-Cabala CA, Prieto VG, Aung PP. From mycosis fungoides to herpetic folliculitis: The significance of deeper H&E tissue sections in dermatopathology. J Cutan Pathol 46(8):624-626, 2019. e-Pub 2019. PMID: 30883857.
24. Morse DC, Chockalingam R, Pye A, Huen A. Hidradenitis suppurativa associated with sorafenib initiation. Dermatol Online J 25(6), 2019. e-Pub 2019. PMID: 31329396.
25. Jensen GL, Dabaja BS, Pinnix CC, Gunther JR, Huen A, Duvic M, Oki Y, Fanale M, Hosing C, Milgrom SA. Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Rep Oncol 11(3):721-728, 2018. e-Pub 2018. PMID: 30519174.
26. Aria AB, Chen L, Huen AO. A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report. SAGE Open Med Case Rep 6:2050313X18795075, 2018. e-Pub 2018. PMID: 30214807.
27. Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol 153(12):1302-1306, 2017. e-Pub 2017. PMID: 28980004.
28. Wieser I, Huen A, Bush AE, Dabaja BS, Duvic M. Periorbital Involvement in Early Stage Mycosis Fungoides. Acta Derm Venereol 97(8):976-978, 2017. PMID: 28421231.
29. Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. Am J Dermatopathol 39(2):121-129, 2017. PMID: 28134729.
30. Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 43(8):688-96, 2016. e-Pub 2016. PMID: 27086658.
31. Tracey EH, Huen AO, Sreih AG, Evans T, Kobrin S, Rubin AI, Rosenbach M. Paraneoplastic microscopic polyangiitis presenting after thymectomy. JAAD Case Rep 2(2):153-5, 2016. e-Pub 2016. PMID: 27222874.
32. Huen A, Fett N. An enormous tumor in a patient with clinically amyopathic dermatomyositis: answer. Am J Dermatopathol 37(11):870, 2015. PMID: 26485242.
33. Chaves J, Huen A, Bueso-Ramos C, Safdar A, Vadhan-Raj S. Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma. Clin Infect Dis 42(8):e72-5, 2006. e-Pub 2006. PMID: 16575720.

Editorials

1. Huen AO, Rook AH. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol 26(2):237-44, 2014. PMID: 24441505.

Abstracts

1. Huen AO, Zanot A, Tran J, Duvic M. Retreatment with Brentuximab Vedotin in Mycosis Fungoides and Lymphomatoid Papulosis. World Congress of Dermatology, International Society of Cutaneous Lymphoma, Singapore, 2023.
2. Iyer S, Rao V, Burns E, Ashu A, Pullokaran L, Vo A, Claussen C, Obi C, Miranda R, Dabaja B, Nieto Y, Hosing C, Lee H, Steiner R, Nair R, Samaniego S, Nastoupil L, Parmar S, Westin J, Fowler N, Ahmed S, Neelapu S, Duvic M, Huen A.. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). American Society of Hematology Annual Meeting, Orlando, FL, 2019. e-Pub 2019.
3. Messer A, Huen AO, Cataldo V, Curry J, Nagarajan P.. Multifocal Primary Cutaneous Mucinous Adenocarcinoma. American Society of Dermatopathology Annual Meeting, November 2018, Chicago, IL, 2018.
4. Duke T, Walker K, Huen A. A case of poziotinib-induced acneiform-like eruption cleared with minocycline. Texas Dermatological Society Annual Fall Meeting, Galveston, TX, 2018.
5. Morse D, Chockalingam R, Pye A, Huen A.. Hidradenitis Supprativa Associated with Sorafenib Initiation. Texas Dermatological Society Annual Fall Meeting, Galveston, TX, 2018.
6. Huen A, Porcu P, Hudgens S, Quaglino P, Cowan R, Floden L, Tsianakas A, Leoni M, Dale S, Duvic M.. Quality of Life in Cutaneous T-Cell Lymphoma Patients Treated with Anti-CCR4 Monoclonal Antibody Mogamulizumab vs. Vorinostat: Results from MAVORIC. Society of Hematologic Oncology. Houston, TX, 2018.
7. Huen AO, Rahbar Z, Talpur R, Li S, Hong EE, Tetzlaff M, Duvic M, Kim YH. Updated Combined Analysis of Two Phase II Studies of Brentuximab Vedotin in Patients with Mycosis Fungoides and Sezary Syndrome. EORTC St. Galen, Switzerland, 2018.
8. Morse D, Muhai D, Torres-Caballa C, Jahan-Tigh R, Huen A.. A Case of Mucous Membrane Pemphigoid Associated with Pembrolizumab. Texas Dermatological Society Annual Fall Meeting. September 2018, Galveston, TX, 2018.
9. Huen AO, Oki Y, Haverkos B, Zain J, Lechowicz MJ, Devata S Korman N, Ramachandren R Pinter-Brown L, Barde P, Nair A,. Tenalisib, a dual P13K δ/γ inhibitor; Safety and efficacy results from an on-going Phase I/lb study in patients with relapsed/refractory T-Cell Lymphoma. American Society of Clinical Oncology Annual Meeting, May 2018, Chicago, IL, 2018.
10. Messer A, Huen AO,. Basals Behaving Badly: A Case Highlighting Current and Emerging Targeted Therapies. Texas Dermatological Society Annual Fall Meeting 2017, September 2017, Bastrop, TX, 2017.
11. Chin AV, Duvic MA, Garg, N, Bassett R, Huen AO.. Gabapentin and pregabalin for the treatment of cutaneous lymphoma associated pruritus. Medical Dermatology Society Annual Meeting. March 2017. Orlando, FL, 2017.
12. Huen A, Zain J, Querfeld C, Haverkos B, Barole P, Kavandar M, Duvic M, Penmetsa K, Oki Y.. Evaluation of RP6530, a Novel dual PI3K δ/γ inhibitor in patients with relaxed/refractory T-Cell Lymphoma. T-Cell Lymphoma Forum. January 2017, San Francisco, CA, 2017.
13. Oki Y, Huen AO, Barde P; Penmetsa K; Ashu AJ, Wilson C, Pullokaran L, Viswanadha S; Duvic M.. A dose escalation study of RP6530, a novel dual PI3K δ/γ inhibitor, in patients with relapsed/refractory t-cell lymphoma. American Society of Mematology Annual Meeting . December 2016, San Diego, CA, 2016.
14. Pickett MM, Sapority RC, Nagarajan P, Huen AO,. EBV-positive lymphoproliferative disorder presenting as a hypersensitivity reaction. Texas Dermatological Society Annual Meeting, September 2016, 2016.
15. Huen AO, Luskin MR, Steart C, Bagg A, Rosenbach M, Perl A.. NPM1 Mutation Associated with leukemia cutis. Platform oral presentation at the Medical Dermatology Society Annual Meeting, San Francisco, CA, March 2015, 2015.
16. Zhang X, Nooruden S, Huen A, Duvic M, Zhang C.. Anti-tumor effects of sapacitabine in cutaneous T-cell lymphoma (CTCL) cells. Society for Investigative Dermatology Annual Meeting, May 2010, 2010.
17. Huen A, DeAngelo D, Fanale M, Vadhan-Raj S. Pharmacokinetic analysis of two dose levels of rasburicase in adult patients with hermatologic malignancies at high or potential risk for tumor lysis syndrome. J Clin Oncol 26(15S), 2008.
18. Zhou X, Huen A, Teegala S, Ji Y, Fayad LE, Hagemeister FB, Vadhan-Raj S. Incidence and significant predicting factors for chemotherapy-induced severe thrombocytopenia in lymphoma patients. J Clin Oncol 26(15S), 2008.
19. Teegala SR, Zhou X, Huen A, Ji Y, Fayad LE, Romaguera JE, Vadham-Raf S.. Risk Factors for neutropenic fever in lymphoma patients receiving chemotherapy. J Clin Oncol 25(185), 2007.
20. Zhou X, Teegala S, Huen A, Ji Y, Fayad LE, Romaguera JE, Hagmeister FB, Vadhan-Raj S.. Risk factors for severe anemia requiring red blood cell transfusions in lymphoma patients receiving chemotherapy. J Clin Oncol 25(185), 2007.
21. Thompson MA, Huen A, Toth BB, Vassilopoulou-Sellin R, Hoff, AO, Murphy WA, Sanjorjo H, Bekele BN, Arbuckle RB, Hagemeister FB. Osteopenia and osteoporosis in untreated non-Hodgkin's lymphoma patients: An important and potentially treatable survivorship issue in lymphoma. J. Clin Oncol 25(185), 2007.
22. Huen A, Ippoliti C, Whimbey E, Ghosh S, Augustin K, Champlin R.. Cytomegalovirus - Immune Globulin (Cytogam) Prophylaxis for the Prevention of Cytomegalovirus Infection and Disease in CMV Serpositive Allogeneic Blood and Marrow Transplantation Receipients. American Society of Hematology Annual Meeting, Philadelphia, PA, 2002.
23. Hicks K, Hachem R.Y., Huen A, Raad II. Myelosuppression and serotonin syndrome associated with linezolid and selective serotonin re-uptake inhibitors (SSRIs). Annual Meeting of the infectious Diseases Society of America. San Francisco. CA, 2001.
24. Huen A, Burgess DS, Hastings RW. Comparison of In Vitro Activity of Voriconazole, SCH- 56592, and Fluconazole against Candida albicans by Time-Kill Methodology. The 1999 International Congress on Clinical Pharmacy and American College of Clinical Pharmacy Spring Research Forum, Orlando, FL, 4/1999, 1999.

Book Chapters

1. b|Huen AOb||, Kim EJ. In: The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. In: Cutaneous Lymphoma Dermatologic Clinic. First. Elsevier Publishing: Philadelphia, PA, 2015.
2. Romaguera J, Huen A.. In: Cancer Matrix Manual. 4th edition. Advanced Medical Publishing, Inc: Madison, WI, 2006.
3. Huen A. Tumor lysis syndrome prevention & management strategies. In: Oncology special edition, 90-96, 2005.
4. Nguyen CN, Huen AO. Pityriasis Lichenoides. In: Fitzpatricks Therapeutics.
5. Huen A.. Cutaneous Lymphoma. In: The MD Anderson Manual of Medical Oncology.